Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Plexpress Announces ADME-Tox Programs for CRO’s

Published: Friday, May 03, 2013
Last Updated: Friday, May 03, 2013
Bookmark and Share
EMA and FDA recommend mRNA testing in ADME-Tox studies for superior sensitivity.

Plexpress has announced dedicated ADME-Tox programs for contract research organizations (CROs). This follows FDA draft guidance suggesting measurement of CYP mRNA levels for ADME-Tox studies, and EMA final guidelines stating that mRNA analysis should be used in drug interaction studies in order to increase the sensitivity of assays.

Plexpress has developed two ADME-Tox screening services for CROs to ensure compliance with regulatory guidelines. For the early screening of compounds of interest, the TRACPACK CYP+ mRNA Screening Service quickly and efficiently identifies unsuitable compounds, allowing them to ‘fail early’ before further time and money is invested.

This service specifically analyzes mRNA expression of the key ADME-Tox markers in a time and cost-effective manner. Plexpress’ TRACPACK INDUCTION, has been developed for the in-depth screening of high priority drug candidates generating data that completely fulfills the global guidelines.

TRACPACK INDUCTION measures both mRNA expression and enzyme activity, using hepatocytes from three different donors.

TRAC’s unique multiplexing with high sample throughput fills the gap between microarrays and traditional targeted approaches such as qPCR, offering numerous time, cost and accuracy benefits to alternative methods.

Plexpress is offering two easy ways for CRO’s to incorporate TRAC into their workflow. The Plexpress Partner Program, an outsourced service which is ideal for small to medium throughput, and the Plexpress Licensing Program suited to a higher throughput with TRAC assays undertaken in-house by the CRO.

Dr. Jari Rautio, CEO of Plexpress, said: “In light of recent recommendations, drug companies are requesting mRNA data for CYP targets to fulfill regulatory guidelines. Our TRAC CRO services and products have been designed to fulfill this exact need and are highly attractive tools thanks to the numerous benefits they offer in comparison to other technologies. TRAC combines gene multiplexing with high sample throughput to increase assay speed and minimize technical variation, providing significant economic and efficiency boosts. We have made it easy for CROs to incorporate TRAC into their workflow with our dedicated Plexpress Partner Program and Plexpress Licensing Program allowing them the choice of outsourcing or fully supported in-house set-up.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
How to Control Shape, Structure of DNA and RNA
Researchers have used computational modelling to shed light on precisely how charged gold nanoparticles influence the structure of DNA and RNA.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos